Analyst consensus rating
Novo Nordisk Analyst Rating: none
Direct answer
Novo Nordisk's consensus rating is none.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $47.16.
Forecast evidence checked September 6, 2026.
Get free Novo Nordisk email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $46.60
- Average price target
- $47.16
- High price target
- $64.11
- Low price target
- $40.23
- Low target gap
- -13.7%
- Target upside
- +1.2%
- High target gap
- +37.6%
- Target range width
- 51.2%
- Consensus rating
- none
- Analysts
- 12
- Evidence date
- September 6, 2026
- Valid through
- September 13, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Novo Nordisk?
Novo Nordisk has a verified none consensus. The same dataset has an average price target of $47.16.
How far are Novo Nordisk's low and high targets from the recorded price?
The low target implies -13.7%, while the high target implies +37.6%.
How many analysts are included in Novo Nordisk's consensus?
The verified consensus includes 12 analysts.
How is Novo Nordisk's target upside or downside calculated?
The average target of $47.16 is divided by the recorded price of $46.60, then one is subtracted to produce +1.2%. This does not guarantee a future return.
When was Novo Nordisk's analyst forecast verified?
The data was verified on 2026-09-06. The dataset is valid through 2026-09-13.